



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

19 September 2019  
EMA/CHMP/790261/2018  
Committee for Medicinal Products for Human Use (CHMP)

## Alectinib hard capsule 150 mg product-specific bioequivalence guidance

<b>Draft Agreed by Pharmacokinetics Working Party (PKWP)</b>	October 2018
<b>Adopted by CHMP for release for consultation</b>	31 January 2019
<b>Start of public consultation</b>	8 February 2019
<b>End of consultation (deadline for comments)</b>	30 June 2019
<b>Draft Agreed by Pharmacokinetics Working Party (PKWP)</b>	September 2019
<b>Adopted by CHMP</b>	19 September 2019
<b>Date of coming into effect</b>	1 April 2020

<b>Keywords</b>	<b><i>Bioequivalence, generics, alectinib</i></b>
-----------------	---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



## Alectinib hard capsule 150 mg product-specific bioequivalence guidance

Disclaimer:

*This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.*

### B. Requirements for bioequivalence demonstration (PKWP)\*

<p><b>BCS Classification**</b></p>	<p><b>BCS Class:</b> <input type="checkbox"/> I    <input type="checkbox"/> III    <input checked="" type="checkbox"/> <b>Neither of the two</b></p> <p><b>Background:</b> Alectinib is considered a low solubility compound.</p>
<p><b>Bioequivalence study design</b></p> <p><i>in case a BCS biowaiver is not feasible or applied</i></p>	<p><b>single dose</b></p> <p><b>cross-over</b></p>
	<p><b>healthy volunteers</b></p>
	<p><input type="checkbox"/> <b>fasting</b>    <input checked="" type="checkbox"/> <b>fed</b>    <input type="checkbox"/> <b>both</b>    <input type="checkbox"/> <b>either fasting or fed</b></p>
	<p><b>Strength:</b> 150 mg</p> <p><b>Background:</b> This is the only available strength.</p>
	<p><b>Number of studies:</b> One</p>

<b>Analyte</b>	<input checked="" type="checkbox"/> <b>parent</b> <input type="checkbox"/> <b>metabolite</b> <input type="checkbox"/> <b>both</b>
	<input checked="" type="checkbox"/> <b>plasma/serum</b> <input type="checkbox"/> <b>blood</b> <input type="checkbox"/> <b>urine</b>
	<b>Enantioselective analytical method:</b> <input type="checkbox"/> <b>yes</b> <input checked="" type="checkbox"/> <b>no</b>
<b>Bioequivalence assessment</b>	<b>Main pharmacokinetic variables:</b> AUC <sub>0-72h</sub> , C <sub>max</sub>
	<b>90% confidence interval:</b> 80.00– 125.00%

\* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C<sub>max</sub>. If high intra-individual variability (CV<sub>intra</sub> > 30 %) is expected, the applicants might follow respective guideline recommendations.

\*\* This tentative BCS classification of the drug substance serves to define whether *in vivo* studies seems to be mandatory (BCS class II and IV) or, on the contrary (BCS Class I and III), the Applicant may choose between two options: *in vivo* approach or *in vitro* approach based on a BCS biowaiver. In this latter case, the BCS classification of the drug substance should be confirmed by the Applicant at the time of submission based on available data (solubility experiments, literature, etc.). However, a BCS-based biowaiver might not be feasible due to product specific characteristics despite the drug substance being BCS class I or III (e.g. *in vitro* dissolution being less than 85 % within 15 min (BCS class III) or 30 min (BCS class I) either for test or reference, or unacceptable differences in the excipient composition).